ArticleAnnals of translational medicine2021
Gender-specific nomogram models to predict the prognosis of male and female lung adenocarcinoma patients: a population-based analysis.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study.Journal of healthcare engineering · 2022Trial
- Novel prognostic signature for lung adenocarcinoma based on immune-related mRNA pairs.Heliyon · 2024Article
- Development and validation of a nomogram for predicting overall survival in patients with stage III-N2 lung adenocarcinoma based on the SEER database.Translational cancer research · 2023Article
- Establishment and validation of nomograms for predicting survival of lung invasive adenocarcinoma based on the level of pathological differentiation: a SEER cohort-based analysis.Translational cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidemiological and clinical prognosis differences between male and female lung adenocarcinoma (LUAD) patients have been frequently reported. To improve prognosis determinations, gender-specific nomogram models should be developed and validated to predict the prognosis of patients with LUAD.
methodsUsing the Surveillance, Epidemiology, and End Results (SEER) database, LUAD patients diagnosed between 2010 and 2015 were used as SEER training and internal validation testing sets. Patients in Tianjin Chest Hospital with postoperative pathological diagnosis of LUAD from January 1, 2015 to October 1, 2016 were considered as Chinese external testing sets. Using the Kaplan-Meier method and log-rank tests, we compared all the included male and female LUAD patients' overall survival (OS) and lung cancer-specific survival (LCSS) rates. The female and male patients from SEER database were randomly divided into training and internal validation groups at a 7:3 ratio. Variables (P<0.05) in the multivariable LCSS Cox regression analysis were independent prognostic predictors of the nomogram models. Harrell's concordance index (C-index), calibration curves, decision curve analysis (DCA) curves, receiver operating characteristic (ROC) curves, and the area under the curves (AUCs) were used to test the calibration and accuracy of the gender-specific nomogram models.
resultsA total of 32,654 LUAD patients (17,372 females and 15,282 males) were identified. Ten variables [age, marital status, tumor site, differentiation grade, derived American Joint Committee on Cancer (AJCC) stage, tumor size, historic stage, surgery, derived AJCC N stage and chemotherapy] were statistically significant in the multivariate LCSS Cox regression analysis, and visualized through the nomogram models. The female and male training nomogram C-indexes were 0.827 and 0.811, respectively. The 3- and 5-year AUCs of the LCSS were 0.881 and 0.872 in the female training set, respectively, and 0.879 and 0.881 in the male training set, respectively. The DCA results indicated that these nomogram models were excellent predictors of LUAD prognosis and can be used to supplement the prognostication of tumor, node, and metastasis (TNM) stage.
conclusionsGiven the different incidence and prognosis of LUAD between men and women, we developed gender-specific nomogram models with good discrimination and calibration capacity to predict 3- and 5-year LUAD-specific survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.